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Objective: The concept of repeatedly connecting an extracorporeal blood pump to produce pancycle suprasystolic inflow
pressures to ischemic limbs is introduced. Balloon catheters allow for limb isolation from the systemic circulation. In the acute
phase, it is assumed that pressure is proportion to flow (Poiseuille’s Law) and in the chronic phase that collateral growth is
related to endothelial shear stress andwall tension. The primary objectivewas to establish that increased flow could be achieved
through collateral circulation in animals and in man with extracorporeal limb hyperperfusion. The second objective was to
develop and test an arterial access system capable of intermittent regional hyperperfusion similar in concept to intermittent
hemodialysis. Finally, to demonstrate the translocation of these concepts into humans facingmajor limb amputation where all
standard treatment options had been exhausted.
Methods: Twelve sheep (6 hyperperfusion and 6 controls) were attached to a cardiac vortex pump and perfused at 200mmHg
pancycle with the superficial femoral artery doubly ligated and isolated from the systemic circulation with a balloon catheter.
Pressure transducers measured carotid and distal femoral pressures and the carotid-femoral index was calculated. To allow
hyperperfusion to be repeated transcutaneously, a peripheral access system (PAS [Allvascular, St Leonards, New SouthWales,
Australia]) was constructed. This device was implanted in the common carotid artery in 8 sheep and opened approximately 3
days aweek for continuous arterial access up to 37 days for 67 openings. To demonstrate these principles in humans, 3 patients
with critically ischemic limbs were hyperperfused intermittently. Digital thermography compared the other limb as controls
and provided objective evidence of the vascular changes.
Results: Themean carotid-femoral index was 0.6 0.01 for controls compared with 1.1 0.28 for the hyperperfusion group
(P< .001). The collateral flow was superior to normal flow (ie, with the superficial femoral not occluded). Continuous access
to the carotid arterial tree via the access device was 25.3 8.8 days with 5 of 8 devices open for the entire observational period
(maximum 37 days). The human ischemic limbs were hyperperfused at 2-4 times the mean arterial pressure producing 3-6
times an increase in pump flowmeasurements intermittently for 53 16 hours. The clinical findings of rest pain, paresthesia,
capillary return, and movement showed dramatic improvement as did thermographic emissions. Major amputation was
avoided in the cases presented.
Conclusion: Blood flow through collaterals can be very significantly augmented by connection to an extracorporeal pumpwith
isolation from the systemic circulation. The pancycle hyperperfusion can be safely repeated by implantation of an arterial access
device. In the longer term, there is evidence of collateral development. When amputation is the only alternative, hypertensive
extracorporeal limb perfusion should be considered. (J Vasc Surg 2008;48:1156-65.)Obstruction to the arterial circulation produces major
morbidity and mortality in the community at large. Myocar-
dial, cerebral, and peripheral vascular obstructions have acute
and chronic syndromes where outcomes are affected by the
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1156“backup circulation” or collaterals. These may also fail as
manifested no more vividly than in the lower limb vascular
tree. More than 150,000 limb amputations occur annually in
the United States (US).1 Approximately 82% of all amputa-
tions are directly related to peripheral vascular disease.2 The
cost to the community is enormous and is estimated to be
$120-150,000 US per patient that includes rehabilitation,
medication, and loss of working days. In addition to this is the
direct cost of the revascularization procedures themselves.
Therefore, reducing the number of amputations would
greatly benefit not just the potential amputees but also society
in terms of reducing the financial burden.
Hypertensive extracorporeal limb perfusion (HELP)
involves taking arterial blood and returning it at a pressure
higher than the mean cardiac pressure. In doing so, the
induced elevated flow results in high fluid shear stresses on the
endothelial surface that will theoretically stimulate growth and
remodeling of collateral vessels. Importantly, the time course
of collateral remodeling needs to be considered. Gene up-
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weeks following vessel occlusion in animals.3
The aims for the present study were threefold. Firstly,
the study sought to demonstrate that by isolating a limb
and hyperperfusing the segment proximal to an occlusion,
greater flow and pressure could be delivered distal to the
occlusion compared to a control. The second aim was to
test an implantable arterial access device for intermittent
and recurrent connection to a HELP pump. Thirdly, the
study tests the efficacy of the HELP technique for 3 pa-
tients with gangrenous limbs for whom two independent
vascular surgeons could only offer major amputation.
MATERIALS AND METHODS
Animal experiments
In the animal model, 2-3-year-old Merino cross wethers
(sheep) weighing between 40 kg to 60 kg were used. This
vascular model was chosen due to its similarities with human
vasculature and widespread availability. The animals were han-
dled according to the Wellcome Animal Laboratories (Royal
North Shore Hospital, Sydney, NSW, Australia) protocols as
an accredited animal laboratory with adherence to Good
Laboratory Practice principles. Ethics committee permission
was obtained prior to the initiation of all experiments.
Inducing high blood flow through collaterals.
Twelve sheep were used for this component of the study (6
controls and 6 HELP treatments). Pressure transducers were
placed in the distal superficial femoral artery (SFA) and the
vessel was occluded. Cannulae were placed in the external iliac
artery (Fig 1) and attached to a Jostra Rotaflow Centrifugal
Pump (Maquet GMBH & Co. KG, Rastatt, Germany). The
pump was then run pancycle at approximately 200 ml/min for
3 hours. The flows and pressures delivered to the occluded
SFA and suction pressures at external iliac were recorded via
the digital pump readout. The control experiments had the
same treatment without pump connection.
The peripheral access system (PAS). The PAS pro-
vides repeatable access to the arterial system. The device,
catheters, and connections were supplied by Allvascular (St
Leonards, NSW Australia). A schematic of the PAS concept
is shown in Fig 2. The essential components comprise a
biocompatible tube that can be anastomosed either end-to-
end or end-to-side with the inflow donor vessel. The exte-
rior connections allow no flow through the tube when not
in use, and an area of tubing that can be clamped to avoid
blood loss when the pump is connected.
The principles of operation are:
1. Suction cannula placed through the central lumen.
2. An inflatable balloon is used to isolate the distal limb
from the systemic circulation.
3. An extracorporeal (cardiac) pump.
4. A return through the access system into the isolated
distal limb with appropriate hemo-reduction valves.
The PAS was tested in eight sheep whose weight varied
from 40 to 60 kg. Two operations were required. To allow
sufficient flow through the system, a minimal access tubeinternal diameter (ID) of 21F was required. As the carotid
ID in sheep was approximately 4-5 mm, a side-to-side
carotid-jugular fistula was created to allow dilatation of the
proximal common carotid artery (CCA). The fistula re-
quired approximately 4 weeks to mature. Suitability for
anastomosis to the access system was determined using
duplex ultrasound, ie, when the CCA ID reached 8 mm.
The second procedure was the end-to-side anastomosis of
the access system with delivery to the exterior.
Fig 3 shows the connections with the suction balloon in
situ with hemo-reduction valves. The PAS was opened every
few days for 3-4 weeks. On four occasions, the cardiac pump
was reconnected to gauge the volume and flow characteristics
in the carotid vessel with a low resistance bed (fistula).
The isolation balloon. The isolation balloon was in-
flated and the blood progressed upward through the center
of the balloon catheter and returning via the outside of the
same catheter but inside the access system (Fig 2). Suction
pressures during flow and inflow were assessed to develop
an impression of how much flow could be pumped through
the system at different pressures.
Intermittent access. The devices were inspected every
3 days for 39.9  9.0 days. After removal of the plunger
and clamping of the silicone tubing, free egress of blood
appropriate for possible pump connection was assessed.
This procedure continued for approximately 1 month in
each sheep, ie, 12 to 15 potential pump connections.
Following euthanasia of the sheep, the systems were exam-
ined at post-mortem.
Human implantation
The data from 3 patients that received HELP treatment
are presented. These patients all had critical ischemia and,
in the opinion of two independent vascular surgeons, had
no treatment option other than a major amputation. Pre-
operatively, informed consent was obtained in all patients.
Human procedures
Following design, bench top, and animal testing of the
PAS, it was approved for humanitarian use by the Human
Research and Ethics Committee of Northern Sydney and
Central Coast Area Health Service, Royal North Shore
Hospital, Sydney, Australia. The PAS was anastomosed to
the common femoral artery (Patients No. 1 and No. 2)
or the axillary artery (Patient No. 3). The PAS was tunneled
through the subcutaneous tissue and was brought out
through the skin. Hemostasis of the anastomosis was
achieved and the anastomosis site was flushed with cepha-
losporin and the wound was closed in layers.
Hyperperfusion. Using the PAS, the patients were
connected to the extracorporeal centripetal pump accord-
ing to the manufacturers operating instructions. Once con-
nected, the patient’s limbs were isolated from the systemic
flow by the inflation of a catheter in the proximal femoral
artery. Before, during, and after the hyperperfusion treat-
ment, blood samples were taken to assess the occurrence of
infection (white blood cell count), hemolysis (plasma free
hemoglobin), and markers for thrombosis, ie, fibrinogen
the p
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(ACT), normal 150-180 seconds, and activated partial
thromboplastin time (APTT) normal 60-80 seconds were
regularly measured to ensure that the patient was receiving
adequate anticoagulation. All patients were on anti-platelet
medication. The other variables “on-pump” were suction
pressures, inflow pressures, flows, derived peripheral resis-
tance, and thermographic profiles (Thermo Tracer
TH7800N, NEC San-ei Instruments, Tachikawa, Tokyo,
Fig 1. A schematic representation of regional limb hyp
Pump inflow comes from the external iliac artery unde
balloon. Pump outflow hyperperfused the collaterals viaJapan). Duplex ultrasound and photoplethysmographywere used for anatomical and blood flow assessments in-
cluding ankle-brachial indices. Pain scores were recorded
on the visual analogue scale (VAS). Pump reconnection was
on clinical grounds, eg, if pain or discomfort were increas-
ing rather than declining (Fig 4).
Human patients
Patient no. 1 (MB 551). A 52-year-old male with a
critical ischemia limb event with a history of chronic occlu-
fusion. The superficial femoral artery has been ligated.
ative pressure. The limb was isolated with an inflated
rofunda femoris artery.erper
r negsion of his distal left popliteal artery. His diagnosis was
ystem
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and stenting of his left common femoral artery and SFA.
This patient suffered from gangrene, ischemic ulcers, isch-
emic neuropathy, and rest pain. In the opinion of two
independent vascular surgeons, this patient had no treat-
ment options other than major amputation. The patient’s
angiogram is shown in Fig 5.
Patient no. 2 (GH 237). A 66-year-old male with
critical limb ischemia due to severe atherosclerosis in his left
SFA and all major arteries below the level of his knee. He
had previously undergone multiple vascular reconstruc-
tions including a femoro-distal bypass. This patient suffered
from ischemic ulcers, ischemic neuropathy, and rest pain
and had a claudication distance of approximately 10 meters.
In the opinion of two independent vascular surgeons, this
patient had no treatment options other than major ampu-
tation.
Patient no. 3 (EC 968). An 85-year-old male with
critical ischemia of his left hand following embolization to
the distal brachial artery 5 months previously. This patient
suffered from gangrene, ischemic ulcers, and rest pain. In
the opinion of two independent vascular surgeons, this
patient had no treatment options other than major
amputation.
Statistical analysis. Statistical analysis using ANOVA
with Turkey’s post-hoc test was performed. This compared
values between the controls and the hyperperfusion group,
as well as the values between the different time points
within each group in the animals. A t test compared general
flow rates and a Mann Whitney test was employed to assess
Fig 2. Delivery and access device (PAS. A schematic sho
indicated by arrows. The inflated balloon isolates the s
compressed form and the cardiac pump is not shown.thermographic parameters.RESULTS
Animals
Inducing high blood flow through collaterals. The
femoral-carotid index (FCI) is the ratio between the fem-
oral arterial and carotid arterial pressures. This was plotted
against time and is shown in Fig 6. The mean and standard
deviations of the hyperperfusion system were compared
with controls. In the first 30 minutes after establishment of
baseline values, the mean FCI in the control group was
0.64 0.048. The mean FCI during the first 30 minutes of
hyperperfusion (after baseline values were achieved) was
0.79 0.065. The mean FCI for the last 30 minutes of the
3-hour observation period were 0.68  0.010 and 1.1 
0.028 for the control and hyperperfusion groups respec-
tively. There was no significant difference in control group
the transcutaneous tube with the blood flow directions
ic circulation from the limb. The plunger is shown in
Fig 3. The PAS with pump connections.wingbetween the first and last 30 minutes (P .05). There were
sheep
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in the hyperperfusion group (P  .001); between the
control and hyperperfusion groups in the first 30 minutes
(P  .001); and between the control and hyperperfusion
Fig 4. Hyperperfusion treatment compared with cont
pressure over the experimental time (240 minutes). The
measure because it controls for normal variations in the
Fig 5. Angiogram of the leg revealing interrupted flow in the
popliteal artery.groups in the last 30 minutes (P  .001).Assessment of the PAS for biocompatibility and
repeated access. In subsequent experiments investigating
the suitability of a prototype to provide vascular access,
eight devices were assessed in vivo using an ovine model.
The devices were observed over a period of 4 weeks.
Although the primary device patency was lost at a median of
20.5 days (average 25.3 8.8), arterial access was available
for the entire 4-week period for five out of eight devices
implanted. These five devices remained functional up to the
day they were explanted. Two devices were not regularly
inspected for arterial access due to problems with the
devices’ components. This did not affect flow through the
host artery and upon explantation of these two devices, an
intimal layer was found to have developed across the anas-
tomoses of both devices. There were no infective or hem-
orrhagic complications associated with any of the eight
devices. The mean time that the device remained implanted
was 39.88  9.0 days (range, 28 to 58).
There was good tissue ingrowth into the Dacron felt
cuff, providing desired anchorage for the device. In four
different animal preparations where the carotid vessels were
hyperperfused, the flow rates were 463 149 mL/minute
using a 12 French (Fr) perfusion catheter. Suction pres-
sures exceeding 120 mm Hg (negative) were avoided, as it
was known that platelet activation could occur at negative
pressure levels when the pumps are used for normal pedi-
atric cardiac applications. The PAS withstood pressures of
up to 200 mm Hg without any adverse affects.
Human hyperperfusion
Perfusion pressures and flows or the various vessels are
summarized in Table I. In total, these patients received
53.3  4.6 hours of hyperperfusion treatment each, over
his graph shows the change in relative femoral blood
of femoral pressure to carotid pressure was used as the
systemic blood pressure during the experiment.rols. T
ratiotwo sessions (treatment 1 of 26.0 6.6 hours; treatment 2
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were separated by approximately 7 days ‘non-treatment’.
Fig 6 is an example of the pressure and flow relationships
over time. The short-term thermographic results are dem-
onstrated in Fig 7. Initial pre-pump emissions on the left
are less than the asymptomatic right limb (Fig 7, a). On
pump, the situation reverses (Fig 7, b and c). In Fig 7, d, the
surface temperature is greater than the patent contralateral
anterior tibial bypass graft. Fig 8 demonstrates the long-
term outcomes at 10 months following hyperperfusion.
The salvaged limb is warmer than the contralateral normal
limb (ABI 1.0). Fig 8, b demonstrated the superior
temperature gradients in the hyperperfused limb. The ther-
mographic emissions in the upper limb patient were com-
pared with a reference point, these results are summarized
in Table II. The ischemic finger without gangrene was the
fifth finger, left hand. The control was the corresponding
finger on the right hand. The finger had tenderness and rest
pain. There was a significant reduction in thermal emissions
of the left fifth finger compared to the right fifth finger (P
.01). On-pump, the affected finger became warmer (P 
.01). Initially off-pump, temperatures resumed to the pre-
pump levels. Gradually the temperatures became the same
as the control after 4 weeks (P  .4). The clinical findings
only vaguely followed this improvement cycle, which
tended to be continuous.
Clinical findings. The pain scores (1-10) are shown at
Fig 9. At 2 months, pain scores were (0, 0, and 1). Im-
provement continued post-pump with demarcation of gan-
Fig 6. Pressure and flow measurements of both hyperperfusion
treatments showing a continuously decreasing trend in pressure
with a slight increase in overall blood flow.
Table I. Various flow and pressure relationships in differe
Vessel Base flow (ml/min) Pump flow
SFA 86 309  41
Profunda 122 780  110
Axillary 206 494  98
SFA, Superficial femoral artery.grene, improvement of claudication, and improvement ofischemic neuropathy. The gangrenous toes were removed
in 1 patient.
Complications. Excessive suture-hole bleeding was a
common problem when connected to the pump and per-
fused at pancycle suprasystolic pressures – especially with
systemic anticoagulation. There were no clinical infections.
When the access system was removed from the axillary
artery in the hand hyperperfusion patient, the vessel was
very friable and replaced with a polytetrafluoroethylene
(PTFE) interposition graft.
DISCUSSION
The acute sheep flow model demonstrates that high
inflow pressures can be propagated to the distal arterial tree.
The strengths of the system relate to its simplicity, repro-
ducibility, cost effectiveness, and easy pump attachments.
The main weakness is the difficulty in creating a chronic
model because of arterial size discrepancy. This is shown no
more dramatically than the need to create a carotid arterio-
venous fistula initially, to test biocompatibility with the
access system.
The human examples demonstrate some translation of
concept from the animal experiments. The main feature is
the ease of creating increased distal flow by increasing
proximal flow (Table I). The 3 patients suggest long-term
effectiveness (longest follow-up 20 months). There is only
minor improvement in distal pressures long term, although
symptoms, thermographic findings, and ultrasonic veloci-
ties (particularly diastolic) are encouraging (Table III).
Material requirements
The pump. The selection of HELP pump was central
to intermittent use of regional hyperperfusion. A portable
cardiac pump with heparin-bonded connections to the
delivery and access device, causing minimal red cell damage
with digitized flow and pressure measurements selected.
The flow dependency of the pump was an added safety
feature. In cases of high resistance, the pressure would
remain constant with a consequent reduction of flow. A
vortex pump was optimal for regional hyperperfusion. Dur-
ing all of the hyperperfusion episodes, the plasma-free
hemoglobin was normal.
Access system design. The requirement for safety and
efficacy of the access system related to the minimization of
thromboembolic phenomena, infection, and ease of recur-
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exercise, systolic pressures in normal people may reach 250
mm Hg with very low diastolic pressures reflecting maximal
peripheral vasodilatation. At foot level, the hydrostatic
column may add up to 100 mm Hg, ie, a total at the foot
level of 350 mm Hg. Regional hyperperfusion imitates peak
exercise pancycle with the patient lying supine. The normal
flow in the lower limb is 350 ml/min and may reach 6 L/m
during exercise. The calf flow is approximately 125 ml/min.4
At calf level through a 7 mm ID with a 12Fr central
catheter, it is possible to achieve flow through collaterals,
which were in excess of non-diseased vessels at rest.
Thermography. The monitoring of the regional hy-
perperfusion effects on ischemic limbs assumes consider-
able importance. To initiate collateral development, the
PAS was designed to provide intermittent multiple treat-
ments for 10-12 hours three times a week. The concept is
similar to that of hemodialysis in chronic renal failure. The
role of thermography was to determine how often regional
hyperperfusion had to be initiated by assessing the rate of
decline of flow through collaterals after removal of the
pumps. The relationship between temperature isotherms
and skin blood flow has been well established. Compared to
Zenon 133 which is regarded as the “Gold Standard”,5
computerized thermography is a rapid, non-invasive tech-
Fig 7. Thermographic study of patient FW with an isch
while (b), (c), (d) demonstrate skin perfusion during thnique where associated software enables the statistical anal-ysis of the recorded image. The optimal use of this device is
selection of amputation level6 that is of great relevance in
monitoring the effects of regional hyperperfusion.
Pressure and flow findings
The animal HELP experiments indicated an increase of
pressure can be propagated through collateral pathways.
The 3 patients also confirm that HELP can result in clinical
improvement. Development of an implantable access de-
vice for recurrent intermittent access also appears to be
feasible up to 28 days. The marriage of these two separate
concepts is underpinned by many animal experiments and
human observations related to collateral development. El-
evated endothelial shear stress has been implicated as the
crucial factor in collateral development.7-10 Shear is directly
related to the pressure gradient across a collateral bed. The
need for intermittent access relates to the time course
requirements for “up regulation” of the genetic control of
collateral development. This appears to be approximately
three weeks.11 The modulating effect of wall tension also
needs to be considered as collateral development dilates
collateral vessels due to increased perfusion pressure. Shear
stress decreases as vessels dilate, thereby reducing the stim-
ulus for collateral development.
Manipulation of collateral pathways. The pressure
left lower limb. In (a), the patient is resting, off-pump
erperfusion phase.emicand flow data suggests direct relationship between pressure
limb
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pathways (Table I). What is not clear is the optimal ap-
proach to maximize long-term collateral stimulation. Flow
can be defined and the pressure varied (Fig 6) or the
pressure made constant and the flow varied. Another im-
ponderable is the role of simultaneous pharmacological
Fig 8. Thermographic study of (a) of left lower limb
compared to the normal contralateral limb (ankle brachia
as demonstrated in (b) when compared to the “normal”
Table II. Area analysis-comparison of the left and right
hands in patient 3. Thermographic readings of a left
upper limb hyperperfusion for ischemic gangrene. The
right fifth finger was used as a control. The analysis
illustrated the time period to regain normal perfusion
Date
Pump
status Right Left Difference P value
Aug 28, 2007 Pre 30.1 27.8 2.3 .01
Sep 10, 2007 Pre 30.5 32.9 2.4 .01
Sep 11, 2007 Post 34.8 32.2 2.6 .01
Oct 11, 2007 Post 26.9 26.8 0.1 .4infusions. Vasodilators have been used occasionally, usuallyin between infusions. Do they have a negative impact on
collateral growth as they reduce the shear stress? Further
data is required to determine the optimum parameters such
as maximum pressures and flows for stimulating collateral
growth. The replacement of the normal pulsatile flow for
continuous flow also may have a beneficial impact. The
capillary fragility is related to the pulse pressure. As the
flow is continuous, this may mitigate against high inflow
pressures. Especially important is improvement in dia-
stolic flow which may have applications in cerebrovascu-
lar disease where hemorrhagic infarct conversion is an
important consideration-flow can be increased without
increasing peak pressures.
The importance of increasing the pressure gradients
across a collateral bed has many clinical analogies. Patients
routinely hang their ischemic limbs over the end of the bed
to improve rest pain using the hydrostatic effect to increase
the pressure gradient across the collateral bed. This is also
evident in the common symptom of nocturnal rest pain.
The pain does not occur during the day because of the
line of Patient MB eight months post-hyperperfusion
x1.0). Skin blood flow on the treated leg was superior
.tibial
l indegravitational effects across an occluded major vessel. Pa-
line.
ble.
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have worsening of their ischemic presentation, either ulcer-
ation or claudication, which usually reverses with the rever-
sal of the pump failure. In patients with aorto-bifemoral
disease and SFA occlusion, bypassing of the aorto-femoral
segment provides an increased pressure head at the femoral
level, which may avoid distal bypass.
Most patients who present with a SFA occlusion do not
lose their limb due to the development of collaterals. How-
ever, time is required for these collaterals to develop. In fact
many patients are not aware that occlusion of a major vessel
has occurred as they remain asymptomatic due to collateral
development. Where critical limb ischemia is treated with a
bypass procedure that is initially successful but then oc-
cludes at 3 to 4 weeks, the limb will usually be saved.
CONCLUSIONS
Collateral blood flow in a limb can be augmented by
connection to an extracorporeal blood pump. The PAS
Fig 9. Patient pain level (1-10) and time




Rest pain Yes No
Gangrene Yes No
Ulceration Yes Healed (Toes lost)
Claudication (m) 15 500
ABI/PPG 0.20 0.36
Peak/end diastolic
velocity (cm/sec) 60/21 (popliteal) 123/60
Follow-up (months) 20
ABI, Ankle-brachial index; PPG, photoplethysmography; N/A, not applicaallows safe and repeated access to the arterial tree. Hyper-perfusion can be suspended when the peripheral resistance
declines so that the pressure required to create a specific
flow is similar to the normal mean cardiac pressure. Rein-
stitution of hyperperfusion is based upon clinical grounds.
Isolated regional hyperperfusion is suggested when ampu-
tation is the only treatment alternative.
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Critical limb ischemia (CLI) remains a major unmet public
health concern in the United States. Despite therapies that include
bypass surgery and a vast array of endovascular options, there
remain a substantial number of patients that because of distal
extent of disease, absent autogenous conduit, or associated co
morbidities do not have revascularization options. These patients
are left with poor quality of life and the frequent need for major
amputation. To date, several pharmacologic and biologic therapies
have demonstrated the ability to improve limb perfusion but have
not as yet demonstrated a beneficial effect on the clinically mean-
ingful endpoint of amputation-free survival. As such there remains
a dire need for an effective minimally invasive therapy for the
no-option or poor-option patient with CLI.
The authors have described a highly innovative procedure that
could potentially meet this need. They have developed a minimally
invasive technique to temporarily perfuse the ischemic extremity at
supra-physiologic blood pressures that are isolated to the affected
extremity. This technique, described as Hypertensive Extracorpo-
real Limb Hyperperfusion (HELP), can be developed for chronic
use. The appeal of HELP is that it may have an acute beneficial
effect on perfusion as well as a delayed effect through increased
formation of collateral blood vessels due to the temporary eleva-convincing preclinical data that perfusion improves with HELP in
a large animal hind limb ischemia model and have provided evi-
dence of feasibility in a small safety study in no-option patients.
The next step in the development of this technique would be
to perform a clinical trial. Unfortunately this is a significant hurdle
in the “no-option” CLI patient population. It is difficult to con-
duct trials in patients with CLI because of patient heterogeneity
and frequent associated co-morbidities. This group of patients that
may present with rest pain through extensive tissue loss and adverse
events are common in such trials. Currently available surrogate
endpoints to measure limb perfusion are not accurate. Though the
natural history of untreated CLI is poor, adjudicated outcomes
data in this patient population are lacking. The need for a control
group to truly assess the efficacy of this therapy further complicates
study design and patient recruitment. In the current study, the few
patients treated by the authors had very different vascular pathol-
ogies and proof of efficacy is lacking.
The authors are to be congratulated for bringing forward an
exciting concept for the treatment of a cohort of patients with few
options and a poor quality of life. The next step, to conduct a
well-designed clinical trial to demonstrate proof of efficacy will be
equally challenging.
